Market News
- Boundless Bio breaks IPO lull with $100M fundraiseby Gwendolyn Wu (BioPharma Dive – Latest News) on March 28, 2024
The startup’s performance will test investors’ appetite for early-stage drugmakers, as Boundless has only advanced as far as Phase 1 clinical trials.
- Which drugs are most likely to be approved in Non-infectious Uveitis?by kgi-admin (Pharmaceutical Technology) on March 27, 2024
Non-infectious Uveitis disease is an indication for drug development with over 10 pipeline drugs currently active according to GlobalData.
- Which drugs are most likely to be approved in Choroidal Disease?by kgi-admin (Pharmaceutical Technology) on March 27, 2024
Choroidal Disease disease is an indication for drug development with over 40 pipeline drugs currently active according to GlobalData.
- Which drugs are most likely to be approved in Bipolar I Disorder?by kgi-admin (Pharmaceutical Technology) on March 27, 2024
Bipolar I Disorder disease is an indication for drug development with over 7 pipeline drugs currently active according to GlobalData.
- Which drugs are most likely to be approved in Mixed Pain (Nociceptive Pain/Neuropathic Pain)?by kgi-admin (Pharmaceutical Technology) on March 27, 2024
Mixed Pain (Nociceptive Pain/Neuropathic Pain) disease is an indication for drug development with over 270 pipeline drugs currently active according to GlobalData.
- Which drugs are most likely to be approved in Somatic Pain?by kgi-admin (Pharmaceutical Technology) on March 27, 2024
Somatic Pain disease is an indication for drug development with over 150 pipeline drugs currently active according to GlobalData.
- Which drugs are most likely to be approved in Nociceptive Pain?by kgi-admin (Pharmaceutical Technology) on March 27, 2024
Nociceptive Pain disease is an indication for drug development with over 190 pipeline drugs currently active according to GlobalData.
- Which drugs are most likely to be approved in Primary Mediastinal B-Cell Lymphoma?by kgi-admin (Pharmaceutical Technology) on March 27, 2024
Primary Mediastinal B-Cell Lymphoma disease is an indication for drug development with over 140 pipeline drugs currently active according to GlobalData.
- Which drugs are most likely to be approved in Tenosynovial Giant Cell Tumor?by kgi-admin (Pharmaceutical Technology) on March 27, 2024
Tenosynovial Giant Cell Tumor disease is an indication for drug development with over 10 pipeline drugs currently active according to GlobalData.
- Which drugs are most likely to be approved in Stem Cell Transplantation?by kgi-admin (Pharmaceutical Technology) on March 27, 2024
Stem Cell Transplantation disease is an indication for drug development with over 20 pipeline drugs currently active according to GlobalData.
- Which drugs are most likely to be approved in Lentivirus Infections?by kgi-admin (Pharmaceutical Technology) on March 27, 2024
Lentivirus Infections disease is an indication for drug development with over 520 pipeline drugs currently active according to GlobalData.
- FDA Approves Roche’s Cobas Malaria Test, Designed to Screen for Malaria in Potential Blood Donorsby OncLive articles on March 27, 2024
Action marks the first FDA-approved blood screening test for malaria.
- Moderna gets Blackstone backing for flu vaccine R&Dby Delilah Alvarado (BioPharma Dive – Latest News) on March 27, 2024
An arm of the private equity firm pledged up to $750 million in funding for Moderna’s flu shot development, in exchange for milestones and royalties.
- European study finds popular ALS drug ineffectiveby Jacob Bell (BioPharma Dive – Latest News) on March 27, 2024
The failure of a medicine known as TUDCA is yet another disappointment for ALS patients, as it comes just after Amylyx’s therapy Relyvrio proved unsuccessful in confirmatory testing.
- FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertensionby OncLive articles on March 27, 2024
Winrevair is the first FDA-approved activin signaling inhibitor therapy for pulmonary arterial hypertension.
- Challenges in Trial Access and Treatment for Women with Chronic Illnessesby OncLive articles on March 27, 2024
In this Pharmaceutical Executive video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, discusses the specific challenges women with chronic illnesses face when it comes to accessing and participating in clinical […]
- Deerfield Agency Appoints Bill Veltre as Executive Vice President and Head of Mediaby OncLive articles on March 27, 2024
Veltre will develop the company’s media and digital strategy.
- Stakeholder Capitalism: Q&A with Meg Alexander, Chief Strategy Officer at Ovid Therapeutics (Part 2)by OncLive articles on March 27, 2024
Alexander continues her conversation, touching on topics like disinformation and diversity in clinical trials.
- Pharma Pulse 3/27/24: Patients Hate ‘Forever’ Drugs—Is Wegovy Different? Low Melatonin Can Increase Risk of Neurological Disorders & moreby OncLive articles on March 27, 2024
The latest news for pharma industry insiders.
- Navigating Healthcare with Patients at the Centerby OncLive articles on March 27, 2024
Webinar Date/Time: Thursday, April 18, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST